Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Agarwal, Neeraj, Azad, Arun A, Carles, Joan · The Lancet · 2023